Bertrand William C JR — SEC Form 4 filings
SEC reporting owner CIK 1291937. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-18.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-01-12 to 2026-06-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 10 legs across 5 filings — 264,944 shares, $40,930 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: sale of 13,599 shares @ $0.67 ($9,152) in Adaptimmune Therapeutics PLC, filed 2024-01-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Adaptimmune Therapeutics PLC (ADAP) | Chief Operating Officer | 7 | — | 10 legs · 264,944 sh · $40,930 | 4 |
| ARDELYX, INC. (ARDX) | Director | 3 | — | — | 8 |
Form 4 filings — Bertrand William C JR
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-18 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 12,345 @ $0 · Grant/award (A): 26,455 @ $0 · Grant/award (A): 39,715 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 207,000 @ $0.01 | EDGAR |
| 2025-06-23 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 19,390 @ $0 · Grant/award (A): 41,551 @ $0 · Grant/award (A): 54,059 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 1,612,032 (derivative) @ $0 · Grant/award (A): 1,074,696 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 5,584 @ $0.58 | EDGAR |
| 2025-01-15 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 4,268 @ $0.59 · Sale (S): 5,471 @ $0.59 · Sale (S): 9,803 @ $0.57 | EDGAR |
| 2024-06-17 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 11,023 @ $0 · Grant/award (A): 40,243 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 2,544,432 (derivative) @ $0 · Grant/award (A): 565,416 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 4,681 @ $0.79 · Sale (S): 5,309 @ $0.67 · Sale (S): 13,599 @ $0.67 | EDGAR |
| 2024-01-12 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 4,009 @ $0.84 · Sale (S): 5,220 @ $0.85 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1291937 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →